Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) Shares Outstanding (Diluted Average): 2012-2024

Historic Shares Outstanding (Diluted Average) for Mimedx Group (MDXG) over the last 13 years, with Dec 2024 value amounting to $149.0 million.

  • Mimedx Group's Shares Outstanding (Diluted Average) rose 0.50% to $149.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.7 million, marking a year-over-year increase of 0.50%. This contributed to the annual value of $149.0 million for FY2024, which is 2.11% up from last year.
  • Per Mimedx Group's latest filing, its Shares Outstanding (Diluted Average) stood at $149.0 million for FY2024, which was up 2.11% from $146.0 million recorded in FY2023.
  • Over the past 5 years, Mimedx Group's Shares Outstanding (Diluted Average) peaked at $149.0 million during FY2024, and registered a low of $108.3 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $146.0 million (2023), whereas its average is $136.0 million.
  • Data for Mimedx Group's Shares Outstanding (Diluted Average) shows a peak YoY rose of 29.27% (in 2023) over the last 5 years.
  • Mimedx Group's Shares Outstanding (Diluted Average) (Yearly) stood at $108.3 million in 2020, then rose by 1.94% to $110.4 million in 2021, then rose by 2.32% to $112.9 million in 2022, then climbed by 29.27% to $146.0 million in 2023, then increased by 2.11% to $149.0 million in 2024.